Qinlock (ripretinib) — United Healthcare
Cutaneous melanoma
Initial criteria
- Diagnosis of cutaneous melanoma
- AND disease is unresectable or metastatic
- AND positive for activating mutations of KIT
- AND disease progression, intolerance, and/or projected risk of progression with BRAF-targeted therapy
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Qinlock therapy
Approval duration
12 months